IN01 / In3Bio - LARVOL DELTA

Anti-EGF antibodies significantly improve the activity of BRAF and KRAS inhibitors in preclinical models (AACR 2022) - "In this study, we tested if antibodies generated by vaccination with IN01 (biologic fusion molecule), could improve the antitumor activity of encorafenib and sotorasib in BRAF and KRAS colorectal (CRC) and non-small cell lung cancer (NSCLC) cell lines. Cell lines with BRAF V600E (HT29, CRC) and KRAS G12C mutations (H2122 and H23, NSCLC) were used. Anti-EGF VacAbs potentiate the antitumor effects of encorafenib and sotorasib in cancer cell lines more efficiently than cetuximab and panitumumab. Our data provide a rationale for clinical trials testing the combination of anti-EGF VacAbs with targeted inhibitors in BRAF and KRAS mutant CRC and NSCLC patients. (1)“Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells” García-Roman S, Molina-Vila MA, et al."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AKT1S1 • ALK • KRAS

MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients (GlobeNewswire) - "IN3BIO Research Limited...show significant promise and appear to be more tolerable for patients, announces today that it has received Clinical Trial Application approval from the British Medicines & Healthcare Products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial of its colorectal cancer vaccine....IN3BIO will trial its innovative anti-epidermal growth factor (EGF) vaccine, IN01, in combination with small molecule inhibitors (SMIs) in patients suffering from KRAS, NRAS, or BRAF mutated colorectal cancer (CRC). IN3BIO will enroll 30 subjects in two cohorts, and intends to conduct the trial in Eastern Europe, Spain, France, and the United Kingdom."

New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

IN3BIO gains approval for Phase I/II clinical trial (PRNewswire) - “IN3BIO…announced today that the company has received the Clinical Trial Application approval from the Bulgarian Drug Agency and Ethical Committee to initiate a Phase I/II clinical trial of its colorectal cancer vaccine in Bulgaria. IN3BIO will trial its innovative anti-EGF vaccine IN01, in combination with small molecule inhibitors (SMIs) in patients suffering from KRAS or NRAS (Cohort A) or BRAF (Cohort B) mutated colorectal cancer.”

New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor